Parker will maintain his oversight of the company’s financial operations through his final day in November. The San Francisco-based firm has initiated an external search to identify his successor as it navigates a broader leadership transition. This change follows the departure of David Chang, who stepped down after an eight-year tenure leading the organization. The transition reflects a new era for Allogene as the company reshapes its management structure under Roberts.
Allogene Therapeutics CFO Geoffrey Parker to Step Down
Geoffrey Parker, the longtime financial architect at Allogene Therapeutics, will retire on November 6, marking another significant shift in the company’s executive suite. The departure comes shortly after the biotechnology firm elevated former Chief Medical Officer Zachary Roberts to the role of president and chief executive officer.
When reusing this material a link to Money Talk is required.





Comments (0)
No comments yet. Be the first!